PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab for Patients Suffering From Metastatic Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 14 May 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PERSEUS-1
- 21 Dec 2018 Status changed from not yet recruiting to recruiting.
- 15 Nov 2018 Planned initiation date changed from 8 Oct 2018 to 30 Nov 2018.
- 06 Sep 2018 Planned initiation date changed from 1 Aug 2018 to 8 Oct 2018.